Flexible ligand docking studies of matrix metalloproteinase inhibitors using Lamarckian genetic algorithm

Daru

Volumn 12, Issue 1, 2004, Pages 1-10

  Dadrass, Orkideh Ghorban ^a   Sobhani, Armin Madadkar ^b   Shafiee, Abbas ^a   Mahmoudian, Massoud ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AutoDock; Computer aided molecular modelling; Flexible ligand docking; MMPIs; MMPs; Rational drug design

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ALGORITHM; ARTICLE; COMPUTER AIDED DESIGN; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FLEXIBLE LIGAND DOCKING; GENETIC ALGORITHM; MOLECULAR MODEL; MONTE CARLO METHOD; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; X RAY CRYSTALLOGRAPHY;

EID: 3042692986     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Murphy G, Docherty AJ. (1992) The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol. 7:120-5.
2. Matrisian LM. (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 6:121-5.
3. Murphy G, Hembry RM. (1992) Proteinases in rheumatoid arthritis. J Rheumatol Suppl. 32:61-4.
4. Overall CM, Wiebkin OW, Thonard JC. (1987) Demonstration of tissue collagenase activity in vivo and its relationship to inflammation severity in human gingiva. J Periodontal Res. 22:81-8.
5. Peress N, Perillo E, Zucker S. (1995) Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J Neuropathol Exp Neurol. 54:16-22.
6. Murphy G, Reynolds JJ, Hembry RM. (1989) Metalloproteinases and cancer invasion and metastasis. Int J Cancer. 44:757-60.
7. Becket RP, Davidson AH, Drummond AH, Huxley P, Whittaker M. (1996) Recent advances in matrix metalloproteinase inhibitor research. Drug Discuss. Today. 1:16-26.
8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. (2000) The Protein Data Bank. Nucleic Acids Res. 28:235-42.
9. Whittaker M, Floyd CD, Brown P, Gearing AJ. (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 99:2735-76.
10. Abagyan R, Totrov M. (2001) High-throughput docking for lead generation. Curr Opin Chem Biol. 5:375-82.
11. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew KR, Olson AJ. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry. 19:1639-1662.
12. Goodsell DS, Olson AJ. (1990) Automated docking of substrates to proteins by simulated annealing. Proteins: Str. Func. Genet. 8:195-202.
13. HyperChem 7. Hypercube, Inc.2002.
14. Gasteiger J, Marsili M. (1980) Iterative partial equalization of orbital electronegativity - A rapid access to atomic charges. Tetrahedron. 36:3219-3228.
15. Weiner SJ, Kollman PA, Case DA, Singh UC, Ghio C, Alagona G, Profeta S, Weiner P. (1984) A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 106:765-784.
16. Stote RH, Karplus M. (1995) Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Proteins. 23:12-31.
17. Moy, FJ, Pisano MR, Chanda PK, Urbano C, Killar LM, Sung M.L, Powers R. (1997) Assignments, secondary structure and dynamics of the inhibitor-free catalytic fragment of human fibroblast collagenase. J Biomol NMR. 10:9-19.
18. Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT, Campbell JA, Walker K A, Martin R, Van Wart H, Browner MF. (1999) Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol. 6:217-21.
19. Feng Y, Likos JJ, Zhu L, Woodward H, Munie G, McDonald JJ, Stevens AM, Howard CP, De Crescenzo GA, Welsch D, Shieh HS, Stallings WC. (2002) Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. Biochim Biophys Acta. 1598:10-23.
20. Chen L, Rydel TJ, Gu F, Dunaway CM, Pikul S, Dunham KM, Barnett BL. (1999) Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes. J Mol Biol. 293:545-57.
21. Pavlovsky AG, Williams MG, Ye QZ, Ortwine DF, Purchase CF, White, AD, Dhanaraj V, Roth BD, Johnson LL, Hupe D, Humblet C, Blundell TL. (1999) X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci. 8:1455-62.
22. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE. (1998) Discovery of potent, achiral matrix metalloproteinase inhibitors. J Med Chem. 41:3568-71.
23. Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, Gu F, Williams LE, Hynd BA, Janusz MJ, Dunaway CM, Mieling GE. (1999) Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem. 42:4547-62.
24. Cheng M, De B, Almstead NG, Pikul S, Dowty ME, Dietsch CR, Dunaway CM, Gu F, Hsieh LC, Janusz MJ, Taiwo YO, Natchus MG, Hudlicky T, Mandel M. (1999) Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold. J Med Chem. 42:5426-36.
25. Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider C E, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S. (2000) Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. J Med Chem. 43:369-80.
26. Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE. (2001) Heterocycle-based MMP inhibitors with P2′ substituents. Bioorg Med Chem Lett. 11:1009-13.
27. Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison R K, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Hagmann WK. (1997) Inhibition of stromelysin-1 (MMP-3) by P1′-biphenylylethyl carboxyalkyl dipeptides. J Med Chem. 40:1026-40.
28. Natchus MG, Bookland RG, Laufersweiler MJ, Pikul S, Almstead NG, De B, Janusz MJ, Hsieh LC, Gu F, Pokross ME, Patel VS, Garver SM, Peng SX, Branch TM, King SL, Baker TR, Foltz DJ, Mieling GE. (2001) Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines. J Med Chem.; 44:1060-71.
29. Browner MF, Smith WW, Castelhano AL. (1995) Matrilysin-inhibitor complexes: common themes among metal loproteases. Biochemistry. 34:6602-10.
30. Brandstetter H, Engh RA, Von Roedern EG, Moroder L, Huber R, Bode W, Grams F. (1998) Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data. Protein Sci. 7:1303-9.
31. Matter H, Schwab W, Barbier D, Billen G, Haase B, Neises B, Schudok M, Thorwart W, Schreuder H, Brachvogel V, Lonze P, Weithmann KU. (1999) Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis. J Med Chem. 42:1908-20.
32. Grams F, Reinemer P, Powers JC, Kleine T, Pieper M, Tschesche H, Huber R, Bode W. (1995) X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. Eur J Biochem. 228:830-41.
33. Bode W, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H. (1994) The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. Embo J. 13:1263-9.
34. Brandstetter H, Grams F, Glitz D, Lang A, Huber R, Bode W, Krell HW, Engh RA. (2001) The 1.8-A crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J Biol Chem. 276:17405-12.
35. Betz M, Huxley P, Davies SJ, Mushtaq Y, Pieper M, Tschesche H, Bode W, Gomis-Ruth F X. (1997) 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur J Biochem. 247:356-63.
36. Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W. (1995) Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry. 34:14012-20.
37. Gall AL, Ruff M, Kannan R, Cuniasse P, Yiotakis A, Dive V, Rio MC, Basset P, Moras D. (2001) Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. J Mol Biol. 307:577-86.
38. Nar H, Werle K, Bauer MM, Dollinger H, Jung B. (2001) Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J Mol Biol. 312:743-51.
39. Moy FJ, Chanda PK, Chen JM, Cosmi S, Edris W, Levin JI, Powers R. (2000) High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. J Mol Biol 302:671-89.